Patent ID: 7820707

Claim:
A heterocyclic derivative according to formula I wherein R 1 is C 1-4 alkyl or CN, said C 1-4 alkyl being optionally substituted with 1-3 halogens; R 2 is C 1-4 alkyl, C 1-4 alkyloxy, or C 1-5 acyl, said C 1-4 alkyl being optionally substituted with a substituent selected from OH, C 1-4 alkyloxy and NR 7 R 8 or R 2 together with R 3 forms a 5 to 7 membered unsaturated carbocyclic ring optionally comprising a N; R 3 is H or methyl optionally substituted with hydroxy or 1-3 halogens or R 3 together with R 2 forms a 5 to 7 membered unsaturated carbocyclic ring optionally comprising a N; R 4 is hydroxymethyl, CO 2 H or CONR 9 R 10 ; R 5 and R 6 are independently H, C 1-4 alkyl or C 3-8 cycloalkyl or R 5 together with R 6 forms a 5 or 6 membered unsaturated carbocyclic ring optionally comprising a heteroatonnic moiety selected from O and NR 11 ; R 7 and R 8 are independently H, C 1-6 alkyl or C 3-8 cycloalkyl, said C 1-6 alkyl being optionally substituted with hydroxy, C 1-4 alkyloxy or 1-3 halogens; or R 7 and R 8 together with the N to which they are bonded form a 3-6 membered saturated heterocyclic ring; R 9 is H or C 1-4 alkyl optionally substituted with 1-3 groups selected from hydroxy, C 1-6 alkyloxy, NR 12 R 13 , CONR 14 R 15 and Y, wherein Y is a 5-6 membered heteroaryl comprising 1-2 heteroatoms selected from 0, N and S, or wherein Y is C 3-8 cycloalkyl optionally comprising 1-2 heteroatomic moieties selected from O, S, SO 2 and NR 16 , Y being optionally substituted with 1-2 substituents selected from C 1-4 alkyl, CH 2 OH and CH 2 NR 17 R 18 ; or R 9 is C 3-8 cycloalkyl comprising a heteroatomic moiety selected from O, S and NR 16 ; or R 9 and R 10 together with the N to which they are bonded form a 5-6 membered saturated heterocyclic ring optionally comprising a heteroatomic moiety selected from O and NR 16 ; R 10 is H or methyl with the proviso that when R 9 is methyl R 10 must be C 1-4 alkyl or R 10 and R 9 together with the N to which they are bonded form a 5-6 membered saturated heterocyclic ring optionally comprising a heteroatomic moiety selected from O and NR 16 ; R 11 is H or methyl; R 12 is H or C 1-4 alkyl or R 12 and R 13 together with the N to which they are bonded form a 5-6 membered saturated heterocyclic ring optionally comprising a heteroatomic moiety selected from O, S and NR 19 ; R 13 is H, C 1-4 alkyl, CO 2 R 20 or SO 2 R 20 or R 13 and R 12 together with the N to which they are bonded form a 5-6 membered saturated heterocyclic ring optionally comprising a heteroatomic moiety selected from O, S and NR 19 ; R 14 -R 19 are independently H or C 1-4 alkyl; R 20 is C 1-4 alkyl; and m is 1-4; with the proviso that when R 1 is CF 3 , R 2 together with R 3 forms a 6 membered unsaturated carbocyclic ring and R 5 together with R 6 forms a 6 membered unsaturated carbocyclic ring, R 4 cannot be CONH 2 ; or a pharmaceutically acceptable salt thereof.